The safety and efficacy of achieving very low LDL-cholesterol concentrations with high dose statin therapy

Current Opinion in Lipidology

Volumn 17, Issue 6, 2006, Pages 626-630

  Wiviott, Stephen D ^a,b   Cannon, Christopher P ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Acute coronary syndrome; Cholesterol; Coronary artery disease; HMG CoA reductase inhibitor; Safety; Statin

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TIROFIBAN; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ACUTE CORONARY SYNDROME; ANGINA PECTORIS; BLEEDING; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONCENTRATION RESPONSE; CORONARY ARTERY DISEASE; DRUG EFFICACY; DRUG SAFETY; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; LIVER FAILURE; MYOSITIS; PRIORITY JOURNAL; REVIEW; RHABDOMYOLYSIS; STROKE; TREATMENT OUTCOME;

CHOLESTEROL, LDL; CLINICAL TRIALS; CORONARY ARTERIOSCLEROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; META-ANALYSIS; TREATMENT OUTCOME;

EID: 33750906598     PISSN: 09579672     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOL.0b013e328010872d     Document Type: Review

References (29)

1. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97:1440-1445.
2. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360:1623-1630.
3. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360:7-22.
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-1389.
5. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med 1998; 339:1349-1357.
6. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350:1495-1504.
7. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292:1307-1316.
8. Wiviott SD, Cannon CP. Update on lipid-lowering therapy and LDL-cholesterol targets. Nat Clin Pract Cardiovasc Med 2006; 3:424-436.
9. Berry PH, MacDonald JS, Alberts AW, et al. Brain and optic system pathology in hypocholesterolemic dogs treated with a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Am J Pathol 1988; 132:427-443.
10. Neaton JD, Blackburn H, Jacobs D, et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992; 152:1490-1500.
11. Iso H, Naito Y, Kitamura A, et al. Serum total cholesterol and mortality in a Japanese population. J Clin Epidemiol 1994; 47:961-969.
12. Stemmermann GN, Chyou PH, Kagan A, et al. Serum cholesterol and mortality among Japanese-American men The Honolulu (Hawaii) Heart Program. Arch Intern Med 1991; 151:969-972.
13. Feinleib M. Review of the epidemiological evidence for a possible relationship between hypocholesterolemia and cancer. Cancer Res 1983; 43:2503s-2507s.
14. O'Keefe JH Jr, Cordain L, Harris WH, et al. Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal. J Am Coll Cardiol 2004; 43:2142-2146.
15. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004; 44:720-732.
16. Larosa JC, Grundy SM, Waters DD, et al. Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease. N Engl J Med 2005; 352:1425-1435. This randomized trial compared intensive with moderate statin therapy in patients with chronic coronary artery disease showing improved outcomes with intensive statin therapy.
17. Pedersen TR, Faergeman O, Kastelein JJ, et al. High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005; 294:2437-2445. This describes a randomized trial comparison of intensive versus moderate statin therapy in patients with chronic coronary artery disease showing a trend toward improved outcomes with intensive statin therapy.
18. Pasternak RC, Smith SC Jr, Bairey-Merz CN, et al. ACC/AHA/NHLBI Clinical Advisory on the Use and Safety of Statins. Stroke 2002; 33:2337-2341.
19. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291:1071-1080.
20. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA 2006; 295:1556-1565.
21. Blazing MA, De Lemos JA, Dyke CK, et al. The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. Am Heart J 2001; 142:211-217.
22. Cannon CP, McCabe CH, Belder R, et al. Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial. Am J Cardiol 2002; 89:860-861.
23. Ray KK, Cannon CP, McCabe CH, et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005; 46:1405-1410.
24. Wiviott SD, de Lemos JA, Cannon CP, et al. A tale of two trials: a comparison of the postacute coronary syndrome lipid-lowering trials A to Z and PROVE IT-TIMI 22. Circulation 2006; 113:1406-1414.
25. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006; 355:549-559.
26. Cannon CP, Steinberg BA, Murphy SA, et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006; 48:438-445. This is a meta-analsysis of the four major intensive versus moderate statin therapy trials, A to Z, PROVE IT-TIMI 22, IDEAL and TNT showing a consistent reduction in nonfatal cardiovascular events with intensive statin therapy.
27. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-1278. This is a meta-analysis of more than 90 000 patients enrolled in primary and secondary prevention trials of statin vs. placebo. Event reductions are consistent across subgroups and related to absolute reduction in LDL-cholesterol.
28. Wiviott SD, Cannon CP, Morrow DA, et al. Can low-density lipoprotein be too low? The safety and efficacy of achieving very low low-density lipoprotein with intensive statin therapy: a PROVE IT-TIMI 22 substudy. J Am Coll Cardiol 2005; 46:1411-1416.
29. LaRosa JC, Grundy SM, Kastelein JJ, Kostis JB. Safety and efficacy of very low LDL-C levels. A post-hoc analysis of the TNT study. American Heart Association Scientific Sessions 2005 [abstract]. Circulation 2005; 112:662-663